{Reference Type}: Journal Article
{Title}: Role of RUNX2 in breast cancer development and drug resistance (Review).
{Author}: Si W;Kan C;Zhang L;Li F;
{Journal}: Oncol Lett
{Volume}: 25
{Issue}: 5
{Year}: May 2023
{Factor}: 3.111
{DOI}: 10.3892/ol.2023.13762
{Abstract}: Breast cancer is the most common malignancy and ranks second among the causes of tumor-associated death in females. The recurrence and drug resistance of breast cancer are intractable due to the presence of breast cancer stem cells (BCSCs), which are adequate to initiate tumor formation and refractory to conventional remedies. Runt-related transcription factor 2 (RUNX2), a pivotal transcription factor in mammary gland and bone development, has also been related to metastatic cancer and BCSCs. State-of-the-art research has indicated the retention of RUNX2 expression in a more invasive subtype of breast cancer, and in particular, triple-negative breast cancer development and drug resistance are associated with estrogen receptor signaling pathways. The present review mainly focused on the latest updates on RUNX2 in BCSCs and their roles in breast cancer progression and drug resistance, providing insight that may aid the development of RUNX2-based diagnostics and treatments for breast cancer in clinical practice.